News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bristol-Myers Squibb Company (BMY)'s Sprycel May Increase Hypertension Risk, FDA Says


10/11/2011 9:33:08 AM

Bristol-Myers Squibb Co. (BMY)’s leukemia drug Sprycel may increase the risk of a rare condition that causes high blood pressure in the lungs’ arteries, U.S. regulators said today. Health-care providers should evaluate patients for signs of underlying cardiopulmonary disease before starting Sprycel, chemically known as dasatinib, and during treatment. If abnormally high blood pressure known as pulmonary arterial hypertension is confirmed, patients should discontinue the medicine, according to the safety announcement from the Food and Drug Administration.

Read at Bloomberg
Read at Fox News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES